The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.